Acute Headache Treatment Brekiya Launches in United States
Self-injected Brekiya (dihydroergotamine mesylate) is now available by prescription for patients suffering from cluster headaches and migraines with aura.
Brekiya autoinjector is the first and only self-administered dihydroergotamine (DHE) autoinjector approved for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.
According to the manufacturer, Amneal Pharmaceuticals, Inc., Brekiya is available through Walgreens Specialty Pharmacy and Sterling Specialty Pharmacy.
- Approved by the FDA in May 2025
- Dihydroergotamine has been used to treat patients in emergency rooms for decades
- Commercially insured patients may pay as little as $40 for a carton of Brekiya, which includes 4 single-dose autoinjectors
No additional quotes available
Author summary: Brekiya launches for acute headache treatment.
More News
- 11 killed in Kenya plane crash en route to popular tourist area
- Best early Black Friday Walmart deals 2025: 20+ sales out early
- Zydus Wellness appoints Manish Lal as Head, Global Demand and Supply Organization
- Call of Duty: Black Ops 7 trails far behind Battlefield 6 on Steam preorders
- Ultra Pure Water Management in Semiconductor Manufacturing: Insights on Reuse and Quality Control
- MLB: The Last 10 World Series MVPs
- Schenectady launches school zone camera demonstration program
- FTV, GTCR see opportunities in maritime sector’s digital shift; Main Capital invests in Shippingbo; Nordic Capital bets on data analytics with BMLL | PE Hub
- Grokipedia launches after brief crash, accused of copying Wikipedia content - Tech Digest
- The Coming Dementia Crisis—and the Cost of Doing Nothing